Public Release: 

Insilico to present the latest developments in AI for aging biomarkers and age management research

InSilico Medicine, Inc.

IMAGE

IMAGE: Insilico Medicine presents at the 24th Clinical Applications for Age Management Medicine Conference. view more 

Credit: Insilico Medicine

Friday, April 6th, 2018, Baltimore, MD - Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, biomarker development and aging research, is pleased to announce the presentation of its Director of Drug Discovery, Dr. Ivan Ozerov, at the 24th Clinical Applications for Age Management Medicine Conference, April 27, 2018, organized by Age Management Medicine Group.

Dr. Ozerov's presentation "Artificial Intelligence for Aging Biomarkers & Age Management Research" will focus on the recent advances in machine learning techniques that outperform classical approaches in biomarker development and complex genomics, transcriptomics and proteomics problems. The session will be devoted to the development of aging biomarkers and customer-oriented age-management systems that utilize multiple AI-driven approaches stacked into an ensemble and trained on multiple medical and biological data.

"We are very happy to present our research at Clinical Applications for Age Management Medicine Conference, which brings together the leading scientists in aging research. The topic of aging biomarkers is rapidly gaining popularity, and we are happy to be at the leading edge of research and one of the innovation drivers in this area", said Alex Zhavoronkov, PhD, the founder and CEO of Insilico Medicine, Inc.

The 24th Clinical Applications for Age Management Medicine Conference aims to introduce and update physicians on the latest science-based clinical information and sophisticated clinical applications during the eye-opening presentations and interactive panel discussions. The conference's agenda includes the highly instructive topics such as cancer and aging biomarkers, genetics and epigenetics in the clinic, stress management in the prevention of dementia, Alzheimer's, and Parkinson's disease, and many others. The event will be held on April 26-29, 2018.

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. It is the first company applied deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016 and demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the recent papers published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual. One of the latest paper published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The most recent paper published in the Oncotarget journal presented the roadmap to enhancing radioresistance for space exploration and colonization.

###

For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD
zhu@pharma.ai
Website: http://www.Insilico.com

Official Conference Website: http://www.agemed.org

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions.

The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.

Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.